Back

Duration of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) for bifurcation lesions: insights from the ULTRA-BIFURCAT registry

30 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Chronic coronary syndromes: antiplatelets Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Marco Nebiolo

A.O.U. San Giovanni Battista Molinette, Turin (Italy)

5 More presentations in this session

Presentation thumbnail
Antiplatelets and hemorrhagic MI outcome in reperfused STEMI
Doctor K. Vora (Indianapolis, US)
Abstract Slides Video
Presentation thumbnail
Indobufen-based dual antiplatelet therapy in patients with multivessel coronary disease undergoing drug-eluting stent implantation: insight from the OPTION trial
Doctor L. Xu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Dual antiplatelet therapy de-escalation followed by aspirin or P2Y12 inhibitor monotherapy after PCI for acute coronary syndrome: a systematic review and meta-analysis
Doctor C. Laudani (Catania, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
Doctor R. Ibrahim (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
The effect of ticagrelor on patients with acute myocardial infarction and malnutrition
Professor K. Chen (Tianjin, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic coronary syndromes: antiplatelets

The Event

Event poster

ESC Congress 2025

30 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Discussant review - DUAL-ACS
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources